TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04375111

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus anterior plane block
Description: •Serratus anterior plane block will be carried out with the patient lying in the lateral position. After skin disinfection, the ultrasound probe will be applied parallel to and between the 5th and 6th ribs in the mid axillary region, for identification of the superficial latissimus dorsi muscles and deep anterior serratus muscles. Then, 25 ml of isobaric bupivacaine 0.25% will be injected above the serratus anterior muscle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus anterior plane block
Description: •Serratus anterior plane block will be carried out with the patient lying in the lateral position. After skin disinfection, the ultrasound probe will be applied parallel to and between the 5th and 6th ribs in the mid axillary region, for identification of the superficial latissimus dorsi muscles and deep anterior serratus muscles. Then, 25 ml of isobaric bupivacaine 0.25% will be injected above the serratus anterior muscle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus thoracic plane block
Description: •Transversus thoracic plane block will be carried out with the patient lying in the supine position. After skin disinfection, the ultrasound probe will be applied parallel to and between the 4th and 5th ribs connecting at the sternum. Then, 15 ml of isobaric bupivacaine 0.25% will be injected between the transversus thoracic muscle and the internal intercosatal muscle.
Study: NCT06521372

Intervention type: OTHER
Intervention: Magenta AI image analysis tool
Description: MagentaTM is a non-invasive image analysis tool that utilizes artificial intelligence to evaluate 2-dimensional images of denuded mature MII oocytes. The MagentaTM software has been analyzed retrospectively, by Future Fertility. This data displays that a higher MagentaTM score is associated with a higher chance of blastocyst development. Additionally, the MagentaTM software has been validated in a prospective multi-center study, displaying that a higher MagentaTM score correlates to a higher chance of blastocyst development.
Study: NCT06530368

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calisthenic home exercise programs
Description: Participants in the second group were informed about calisthenic home exercise programs face to face and were asked to perform these exercises as home exercises for eight weeks.
Study: NCT05231460

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: narcotic regimen with TAP block
Description: Patient will receive Tap Block to 15ml of 0.5% Ropivacaine and will be administered the following Narcotic Pain Regimen post-operatively:~* PO Oxycodone 5mg, 10mg q4h for moderate and severe pain~* IV Dilaudid 1mg q3h for breakthrough pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: narcotic regimen with no TAP block
Description: Patient will not receive TAP block and will be administered the following Narcotic Pain Regimen post-operatively:~* PO Oxycodone 5mg, 10mg q4h for moderate and severe pain~* IV Dilaudid 1mg q3h for breakthrough pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: non-narcotic regimen with TAP block
Description: Patient will receive Tap Block to 15ml of 0.5% Ropivacaine and will be administered the following Non-narcotic Pain Regimen post-operatively:~* Toradol 15mg q6h~* Tylenol 1000mg q8h~* Gabapentin 100mg three times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: non-narcotic regimen with no TAP block
Description: Patient will not receive TAP block and will be administered the following Non-narcotic Pain Regimen post-operatively:~* Toradol 15mg q6h~* Tylenol 1000mg q8h~* Gabapentin 100mg three times a day
Study: NCT05007002

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-based therapy
Description: Active and passive therapy tasks for proprioception and sensory processing, with use of the Kinarm End-Point Lab (BKIN Technologies Ltd., Canada)
Study: NCT05181111

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Sensor
Description: The sensor measures vital signs including heart rate and respiratory rate, posture and level of physical activity.
Study: NCT06058039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMRA-335140
Description: Participants will receive NMRA-335140 at a dose of 80 mg QD, orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally
Study: NCT05320926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel monotherapy
Description: Patients will be randomized to stop aspirin and maintain clopidogrel after short-term DAPT.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin monotherapy
Description: Patients will be randomized to stop clopidogrel and maintain aspirin after short-term DAPT.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: zotarolimus-eluting stent (Resolute Onyx ®)
Description: zotarolimus-eluting stent (Resolute Onyx ®)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: zotarolimus-eluting stent (Resolute Onyx ®)
Description: zotarolimus-eluting stent (Resolute Onyx ®)
Study: NCT05181111

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual Care Monitoring

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Usual Care Monitoring
Study: NCT05273268

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized nutrition
Description: Personalized nutrition based on individual traits delivered through mobile device app.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Generalized nutrition
Description: General nutrition guidelines currently used by USDA.
Study: NCT05236218

Intervention type: OTHER
Intervention: Discrete Choice Experiment (DCE) Patients DCE Questionnaire
Description: Discrete Choice Experiment (DCE) Patients

Intervention type: OTHER
Intervention: Semi-Structured Interview Patients Interview
Description: First version of questionnaire (readability/comprehension check)
Study: NCT05225857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGA2118
Description: Part 1 - SAD study: SAD participants in various cohorts will receive various single dose of AGA2118 via either SC or IV.~Part 2 - MAD study: MAD participants in various cohorts will receive various multiple doses of AGA2118 Q4W via SC.
Study: NCT05410626

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prolong-release methylphenidate
Description: This randomization, cross-over design study will enroll subjects who receive a stable dose of immediate-release methylphenidate (IR-MPH) for at least 4 weeks. Eligible subjects will be switching from IR-MPH to the first brand prolong-release methylphenidate (PR-MPH) for 4 weeks and switching to another brand for 4 weeks. The study consists of 3 parts: screening, study period, and post-treatment follow-up. The duration of this study will be 8 weeks with 2 visits during the study period. The primary outcome is the efficacy of treatment will be evaluated by SNAP-IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prolong-release methylphenidate
Description: This randomization, cross-over design study will enroll subjects who receive a stable dose of immediate-release methylphenidate (IR-MPH) for at least 4 weeks. Eligible subjects will be switching from IR-MPH to the first brand prolong-release methylphenidate (PR-MPH) for 4 weeks and switching to another brand for 4 weeks. The study consists of 3 parts: screening, study period, and post-treatment follow-up. The duration of this study will be 8 weeks with 2 visits during the study period. The primary outcome is the efficacy of treatment will be evaluated by SNAP-IV.
Study: NCT05824806

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRP Protocol A
Description: Platelet rich plasma protocol A

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRP Protocol B
Description: Platelet rich plasma protocol B

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Hyaluronic acid
Description: Hyaluronic acid
Study: NCT05225857

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part 1 - SAD study: SAD participants in various cohorts will receive a single dose of placebo via either SC or IV.~Part 2 - MAD study: MAD participants in various cohorts will receive multiple doses of placebo via SC.
Study: NCT06282185

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: supervised training program for twelve weeks + usual care + advice about exercise
Study: NCT05508308

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OxyMate
Description: Automated Oxygen Control algorithm (VDL 1.1) coupled with Diamedica Baby CPAP device

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual oxygen control
Description: Guidelines and training in FiO2 titration to achieve a target range of SpO2. Health workers instructed in responding to continuous pulse oximetry readings and alarms
Study: NCT05791968

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Whole blood standard donation
Description: Effects of a standard whole blood donation on iron stores and insulin sensitivity.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Whole blood standard donation
Description: Effects of a standard whole blood donation on iron stores and insulin sensitivity.
Study: NCT04853719

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban 2.5 Mg Oral Tablet
Description: oral anticoagulants plus antiplatelet agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 Mg Oral Tablet
Description: oral anticoagulants plus antiplatelet agent
Study: NCT04996485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab Injection
Description: Pathogenetic therapy with biologic drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab Injection
Description: Pathogenetic therapy with biologic drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab Injection
Description: Pathogenetic therapy with biologic drugs

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Symptomatic therapy
Description: Active external agents, Emollients, systemic retinoids if needed
Study: NCT05449691

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One-stage immediate breast reconstruction
Description: One-stage mesh assisted implant breast reconstruction

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One-stage immediate breast reconstruction
Description: One-stage mesh assisted implant breast reconstruction
Study: NCT05522257

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: [18F]-JK-PSMA-7 PET/CT scan
Description: A \[18F\]-JK-PSMA-7 PET/CT scan will be made to assess the level of tracer uptake in the malignant lesion(s). We expect to make a \[18F\]-JK-PSMA-7 PET/CT scan in 15 out of 60 patients per cohort.
Study: NCT05345717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept Injection
Description: Patient will initiate belatacept therapy and will received 2 cycles of proteasome inhibitor therapy
Study: NCT05476172

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dienogest Pill
Description: The effect of dienogest on endometriosis pain symptoms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norethindrone Acetate
Description: The effect of Norethindrone Acetateon endometriosis pain symptoms.
Study: NCT05340036

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bimaxillary orthognathic surgery using conventional plates
Description: le fort I osteotomy will carried out in the classic way guided by the classic landmarks (maxillary roots apices) as described by Wassmund.~Complete separation of the maxillary segment using chisels and mallets in regular fashion.~Reposition maxilla using the interocclusal wafer while mandible is gently positioned to centric relation position.~Mandible is maintained in place until fixation of the maxilla with plates and screws takes place.~Complete separation of the mandibular segment using chisels and mallets in regular fashion.~Repositioning of mandible using the final interocclusal wafer while condylar segment is gently positioned to centric relation position.~Fixation of mandibular segments with plates and/or screws in regular fashion.~Incision was closed with 4-0 resorbable sutures in a continuous running fashion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bimaxillary orthognathic surgery using patient specific plates
Description: The cutting guide of the maxilla will be placed onto the exposed bony surface and manipulated to the best fit.~Then, the guide will be fixed using four 2.0-mm screws to avoid any mobilization during drilling of the reference holes. Sixteen reference holes will be established using the cutting guide; eight on each side.~Then, a reciprocating saw will be used to perform the planned Le Fort I osteotomy. After adequate maxillary mobilization and removal of bony interferences, the maxilla will be repositioned using the patient-specific osteosynthesis material guided by the previously established reference holes and fixed using 2.0-mm screws.~Then, the mandibular cutting guide will be fixed in the same manner and bilateral sagittal split osteotomy will be carried out.~After adequate mobilization, the mandible will be repositioned by the patient-specific osteosynthesis material using the reference holes made by cutting guide and fixed using 2.0-mm screws.
Study: NCT04923568

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EaseVRx
Description: Participants will experience 2 sessions of the EaseVRx device for chronic pain
Study: NCT05451563

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double-S
Description: Wearable device for intercourse
Study: NCT04590573

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural couple therapy (CBCT), Emotion focused couple therapy (EFCT), Wait-list control (Control)
Description: 5 sessions in CBCT, EFCT and Control (3 hours per session), 6-8 pairs of couples per group and around 7 groups will be held.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioural couple therapy (CBCT), Emotion focused couple therapy (EFCT), Wait-list control (Control)
Description: 5 sessions in CBCT, EFCT and Control (3 hours per session), 6-8 pairs of couples per group and around 7 groups will be held.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural couple therapy (CBCT), Emotion focused couple therapy (EFCT), Wait-list control (Control)
Description: 5 sessions in CBCT, EFCT and Control (3 hours per session), 6-8 pairs of couples per group and around 7 groups will be held.
Study: NCT05081232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MLG (Multi-Layered Perinatal Issue Allograft) Allograft
Description: MLG allografts contains more than 450 bioactive proteins including growth factors and cytokines known to modulate inflammation and promote tissue healing.~MLG is supplied as sterile sheets having dimensions of 2cm x 2cm and a thickness of approximately 0.8-1.0mm thick.~Participants receiving MLG will have it placed around the neurovascular bundle. Placement of the graft should not take over 5 minutes of time to impact overall surgical time length significantly.
Study: NCT05518357

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LILRB4 STAR-T
Description: Subjects with relapsed/refractory acute myeloid leukemia will be enrolled in the study, and Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of STAR-T cells. STAR-T cells will be intravenously infused with a escalated dose of 1E6#3E6#1E7 cells/kg。
Study: NCT06383988

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Support for Caregiver - Generic List
Description: Receive a generic resource list

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Support for Caregiver - Generic List
Description: Receive a generic resource list

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Support for Caregiver - Personalized List
Description: Receive personalized resource list

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention - CONNECT
Description: Receive access to CONNECT tool

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Complete calls with caregiver navigator
Study: NCT06476496

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: A licensed acupuncturist will insert sterile disposable acupuncture needles in the selected body and ear acupoints aiming to alleviate long COVID related pain symptoms. Needles will be removed after 20 minutes of retention. After all the needles are removed, the acupuncturist will insert Pyonex press tack needles (0.3mm) in the participants' left ears and suggest the participants retain them in their ears for up to 5 days.
Study: NCT05852197

Intervention type: DRUG
Intervention: anticoagulant or antiplatelet drugs
Description: combination of anticoagulant or antiplatelet drugs

Intervention type: DRUG
Intervention: anticoagulant or antiplatelet drugs
Description: combination of anticoagulant or antiplatelet drugs
Study: NCT04782570

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verum TMS
Description: Intensity of 100% of the resting motor threshold with iTBS. 600 stimuli applied in bursts of three pulses at 50 Hz given every 200 ms. iTBS will be applied 20 times for 2 s every 10 s.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TMS
Description: Sham stimulation with same protocol, but without magnetic stimulation
Study: NCT05059145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate
Description: Vaginal cream 1%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: 150 mg oral capsule
Study: NCT06027658

Intervention type: BEHAVIORAL
Intervention: RECREATION therapy
Description: Dance as therapy program with speech and movement co-therapy via body activity.

Intervention type: BEHAVIORAL
Intervention: RECREATION therapy
Description: Dance as therapy program with speech and movement co-therapy via body activity.
Study: NCT04548349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Altreno
Description: Acne patients will be assigned to Altreno once daily.
Study: NCT05038878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Patients will be given Elagolix 200 mg orally twice daily for a total of 6 months
Study: NCT04548349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide
Description: Acne patients will be assigned to BPO leave-on gel once daily.
Study: NCT05523427

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Two probiotic strains (L. plantarum and L. acidophilus)
Description: A capsule containing the L. plantarum and L. acidophilus strains is to be administered twice daily for three months in addition to the standard treatment of IBS.
Study: NCT04826367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation-based relaxation exercise group (EG)
Description: the participants in this group will perform the relaxation exercises thrice a week, for 6 weeks.
Study: NCT04658134

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glycine
Description: Oral glycine tablets (100 mg/kg/day) in divided doses
Study: NCT05512585

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: awake prone positioning with advanced respiratory support (high-flow nasal cannula or continuous positive airway pressure)
Description: in this group, healthy subjects will stay in prone position for 20 mins with respiratory support of high-flow nasal cannula or CPAP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: awake prone positioning with advanced respiratory support (high-flow nasal cannula or continuous positive airway pressure)
Description: in this group, healthy subjects will stay in prone position for 20 mins with respiratory support of high-flow nasal cannula or CPAP

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: awake prone positioning with advanced respiratory support (high-flow nasal cannula or continuous positive airway pressure)
Description: in this group, healthy subjects will stay in prone position for 20 mins with respiratory support of high-flow nasal cannula or CPAP

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: awake prone positioning with advanced respiratory support (high-flow nasal cannula or continuous positive airway pressure)
Description: in this group, healthy subjects will stay in prone position for 20 mins with respiratory support of high-flow nasal cannula or CPAP

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: awake prone positioning with advanced respiratory support (high-flow nasal cannula or continuous positive airway pressure)
Description: in this group, healthy subjects will stay in prone position for 20 mins with respiratory support of high-flow nasal cannula or CPAP
Study: NCT05970042

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GameDay Ready
Description: GameDay Ready is a 12-week, group-based behavioral weight management program in which participants will meet in-person once per week at a publicly accessible walking track. The GameDay Ready program promotes increasing physical activity, reducing sedentary time, and improving dietary habits through education, behavioral self-monitoring, and goal setting. Each 60-minute intervention session includes a brief educational component followed by a group discussion of weekly progress. Following a short warmup walk, participants engage in group-based competitive physical activities and then a short cooldown walk. Participants then set individual and group-based goals for the upcoming week and discuss strategies for overcoming barriers to achieving goals. The program is sensitive to intersectional influences of gender, race, and rurality on health; and strategies to enhance motivation are threaded throughout the program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking and General Health Education
Description: Participants receiving the comparison program will complete a 12-week walking and general health education program. Group sessions meet once per week at a publicly accessible walking track, and each 60-minute session consists of a brief educational component on a health topic followed by walking and socializing during the remainder of the session.